The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Herpesviruses infect most Australians and cause recurrent ulcers, birth defects and cancer. Infection lasts lifelong, and spreads to close contacts without obvious clinical signs. Thus disease is hard to prevent. However we can learn much from related animal infections. We have shown that both mouse and human herpesviruses enter mice via cells in the nose. Thus human infections might follow the same route. We will define what body defences work here and whether vaccines can prevent infection.
Understanding HIV Resistance To Entry Inhibitors To Advance The Development Of Novel Antivirals
Funder
National Health and Medical Research Council
Funding Amount
$877,585.00
Summary
We cannot afford to be complacent in the search for improved anti HIV drugs for 2 principal reasons; First, worldwide a staggering 66% of infected individuals who need treatment are still unable to access therapy; and Second, the main reason why most treated patients are now living longer and more healthy lives is because we have never stopped developing newer therapies to provide options for patients. In this study we will develop and test newer drugs that block HIV infection of cells.
Rapid Point Of Care Detection Of Avian Influenza Virus Using Ion-Channel Switch Biosensor
Funder
National Health and Medical Research Council
Funding Amount
$425,400.00
Summary
The project aims to demonstrate a rapid, Point-of-Care test based on the Ion Channel Switch (ICS_) Biosensor for the detection and identification of Avian Influenza (AI) Virus in respiratory specimens. This proposal combines the extensive scientific skills and experience of the Institute of Medical and Veterinary Science (IMVS), Adelaide with the experience and existing capability of Ambri Ltd, Chatswood Sydney, to adapt an existing ICS_ Biosensor for the detection of avian influenza virus in cl ....The project aims to demonstrate a rapid, Point-of-Care test based on the Ion Channel Switch (ICS_) Biosensor for the detection and identification of Avian Influenza (AI) Virus in respiratory specimens. This proposal combines the extensive scientific skills and experience of the Institute of Medical and Veterinary Science (IMVS), Adelaide with the experience and existing capability of Ambri Ltd, Chatswood Sydney, to adapt an existing ICS_ Biosensor for the detection of avian influenza virus in clinical specimens. The existing ICS_ Biosensor has been shown to have reactivity with inactivated Influenza A (H1N1 and H3N2 _ current, circulating human strains) and with recombinant Nucleoprotein. This unique mix of experience and infrastructure will permit the demonstration a rapid, point-of-care test for Avian Flu within the tight six months schedule.Read moreRead less
The Role Of Glycans In Arboviral Disease; From Immunomodulation To Glycotherapeutic Treatment Strategies
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Dengue and chikungunya viruses are leading causes of emerging mosquito-transmitted (arboviral) disease worldwide. Currently there are no available vaccines or therapeutics making combatting these arboviral diseases one of our most pressing global health challenges. Preliminary evidence shows that glycan recognition is critical for disease immunopathogenesis. This project focuses on the role of viral glycans in arboviral disease with the aim of identifying and expanding on new therapeutic targets
Elucidating The Activation Mechanism Of The HIV-1 Envelope Glycoproteins, Gp120-gp41
Funder
National Health and Medical Research Council
Funding Amount
$636,973.00
Summary
Antiretrovirals prolong the life of HIV+ people, however toxicity and resistance issues persist. We aim to understand how the HIV surface proteins effect viral entry in order to identify new antiviral targets.
Hepatitis C virus (HCV) and Human immunodeficiency virus (HIV) infect 200 million and 50 million people world-wide, respectively, and there are no preventative vaccines. The work outlined in this fellowship seeks to understand the structure and function of the major surface proteins of these viruses, their ability to be recognised by the immune system and to develop a novel vaccine for the prevention of HCV.
Delineation Of Receptor-activated Conformational Signalling Pathways In HIV-1 Envelope Glycoproteins
Funder
National Health and Medical Research Council
Funding Amount
$834,478.00
Summary
Although antiretroviral therapy has prolonged the life of people infected with HIV, the virus rapidly develops resistance. Therefore it is essential to develop new antiviral agents to combat HIV infection. The first stages of infection include the process of the virus attaching to cellular receptors and the fusion of viral and cellular membranes leading to entry. In this project we seek to understand how the surface proteins of the virus mediate viral entry and identify new antiviral targets.
Influenza remains an important disease and exacts a high toll in both morbidity and mortality each year. This project will identify the carbohydrates that are utilised by influenza virus to initiate infection throughout the body and map how these carbohydrates interact with the key viral surface proteins. This research will provide new insight into the emergence of new influenza virus strains and cross-species pathogenicity.
Structure And Function Of The Hepatitis C Virus Glycoproteins E1 And E2.
Funder
National Health and Medical Research Council
Funding Amount
$533,828.00
Summary
Hepatitis C virus (HCV) infects approximately 3 % of the global human population with 150,000-200,000 HCV-infected individuals currently living in Australia. Chronic HCV infection is associated with recurrent, progressively worsening liver disease, liver cirrhosis and hepatocellular carcinoma. The current therapy (interferon-ribavirin) is effective in only 40 % of patients and is often associated with severe side-effects. The mechanisms that HCV uses to replicate in liver cells is poorly underst ....Hepatitis C virus (HCV) infects approximately 3 % of the global human population with 150,000-200,000 HCV-infected individuals currently living in Australia. Chronic HCV infection is associated with recurrent, progressively worsening liver disease, liver cirrhosis and hepatocellular carcinoma. The current therapy (interferon-ribavirin) is effective in only 40 % of patients and is often associated with severe side-effects. The mechanisms that HCV uses to replicate in liver cells is poorly understood. In this project we aim to better understand how the viral glycoproteins, E1 and E2, function in the initiation of infection. In particular, we will examine how these glycoproteins bind to liver cell receptors and then mediate virus-cell membrane fusion. These processes lead to the penetration of the HCV genetic material into the cell where it is replicated. These studies are essential for the discovery of new targets for antiviral agents and vaccines.Read moreRead less